{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-033033","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.167929+00:00","generated_at":"2026-06-10T08:39:39.847521+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Akebia: Vafseo approved in Australia; Auryxia 2023 revenue guidance lowered to $170-175M","bullets":["Australia's TGA approved Vafseo (vadadustat) for anemia in dialysis patients; product now approved in 35 countries.","Akebia lowered Auryxia net product revenue guidance for 2023 to $170-175M from $175-180M due to market dynamics.","Company plans to resubmit U.S. NDA for vadadustat by end of Q3 2023.","Appointed Graham Ray (ex-Takeda) as VP, Key Accounts to lead U.S. launch prep and customer engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-033033","json":"https://secwatch.observer/filing/0001628280-23-033033.json","markdown":"https://secwatch.observer/filing/0001628280-23-033033.md","text":"https://secwatch.observer/filing/0001628280-23-033033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/0001628280-23-033033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/akba-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:39:39.847521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}